Arrowhead Pharmaceuticals Inc - Asset Resilience Ratio
Arrowhead Pharmaceuticals Inc (ARWR) has an Asset Resilience Ratio of 59.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ARWR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Arrowhead Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ARWR equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Arrowhead Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arrowhead Pharmaceuticals Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $830.66 Million | 59.96% |
| Total Liquid Assets | $830.66 Million | 59.96% |
Asset Resilience Insights
- Very High Liquidity: Arrowhead Pharmaceuticals Inc maintains exceptional liquid asset reserves at 59.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arrowhead Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Arrowhead Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Camurus AB
ST:CAMX |
Biotechnology | 78.61% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Disc Medicine Inc.
NASDAQ:IRON |
Biotechnology | 85.48% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
Annual Asset Resilience Ratio for Arrowhead Pharmaceuticals Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Arrowhead Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 47.77% | $692.82 Million | $1.45 Billion | -2.97pp |
| 2024-09-30 | 50.73% | $578.28 Million | $1.14 Billion | +12.50pp |
| 2023-09-30 | 38.24% | $292.74 Million | $765.55 Million | -0.55pp |
| 2022-09-30 | 38.79% | $268.39 Million | $691.94 Million | +12.97pp |
| 2021-09-30 | 25.82% | $183.35 Million | $710.15 Million | -7.08pp |
| 2020-09-30 | 32.90% | $171.91 Million | $522.50 Million | +22.35pp |
| 2019-09-30 | 10.55% | $36.90 Million | $349.85 Million | -31.03pp |
| 2018-09-30 | 41.57% | $46.40 Million | $111.61 Million | +2.38pp |
| 2017-09-30 | 39.19% | $40.77 Million | $104.02 Million | -- |
| 2016-09-30 | 0.00% | $0.00 | $128.18 Million | -- |
| 2015-09-30 | 13.26% | $17.54 Million | $132.27 Million | +1.42pp |
| 2014-09-30 | 11.84% | $21.65 Million | $182.82 Million | -12.35pp |
| 2013-09-30 | 24.19% | $9.03 Million | $37.33 Million | +23.55pp |
| 2012-09-30 | 0.64% | $106.50K | $16.53 Million | -3.35pp |
| 2011-09-30 | 3.99% | $634.59K | $15.89 Million | +3.73pp |
| 2005-09-30 | 0.26% | $76.88K | $29.04 Million | -3.83pp |
| 2004-09-30 | 4.09% | $487.89K | $11.92 Million | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more